Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Post by stockgurukingon Oct 03, 2012 12:30pm

307 Views

Post# 20442960

Perfect Storm Brewing

The timing for release of ICO's interim Phase II data this Fall could not be better with the NASDAQ Biotech index being at 14 year high:

-

https://www.stockwatch.com/Quote/Detail.aspx?action=go&symbol=$NBI&region=U&lookup=symbol&snapshot=default

-

And just today Sarepta (NASDAQ: SRPT) is up 160% and $24 after announcing positive Phase II data on their RNA-based technology for treatment of Duchenne Muscular Dystrophy.

-

Based on when the Phase II trial started and some major eye conferences occuring in November the countdown to interim data is likely 30 to 60 days.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario